Literature DB >> 25241256

Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells.

Abderezak Zebboudj1, Mohamed Ali Maroui2, Jacques Dutrieux2, Chafia Touil-Boukoffa3, Mehdi Bourouba3, Mounira K Chelbi-Alix2, Sébastien Nisole4.   

Abstract

Epstein-Barr virus (EBV) is associated with several malignancies, including carcinomas, such as nasopharyngeal carcinoma, and lymphomas, such as Burkitt's lymphoma and Hodgkin's lymphoma. The Latent Membrane Protein 1 (LMP1) is the major oncogene protein of EBV as its expression is responsible for the induction of cell transformation, immortalization and proliferation. Arsenic trioxide was shown to induce a cytotoxic effect on nasopharyngeal cancer cells associated with LMP1 down-regulation. However, the effect of arsenic on EBV-associated lymphoproliferative malignancies has been less studied. We investigated the effect of two different arsenical compounds, arsenic trioxide (As2O3) and sodium arsenite (NaAsO2) on the induction of cell death in P3HR1 cells, an Epstein-Barr virus-positive Burkitt lymphoma derived cell line. Both compounds inhibited cell growth and induced cell death. By flow-cytometry and Western blot analysis, we provide evidence that NaAsO2 induced caspase-dependent apoptosis whereas As2O3 triggered autophagic cell death. Furthermore, we show that NaAsO2 treatment led to a dramatic decrease of the expression level of LMP1 and the cellular protein PML. Importantly, this down-regulation was associated with a reactivation of EBV lytic cycle through the induction of immediate-early proteins Zta and Rta. These results are in agreement with a model in which LMP1 maintains EBV in a latent state by stabilizing PML expression. Altogether, our results suggest that NaAsO2 would represent a better therapeutic candidate than As2O3 in EBV-induced B lymphoma for its capacity to promote viral reactivation.
Copyright © 2014 Elsevier B.V. and Société française de biochimie et biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Arsenic; Epstein–Barr virus; LMP1; Latency; PML

Mesh:

Substances:

Year:  2014        PMID: 25241256     DOI: 10.1016/j.biochi.2014.09.002

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

1.  Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway.

Authors:  Horacio Gonzalez; Carolina Lema; Robert A Kirken; Rosa A Maldonado; Armando Varela-Ramirez; Renato J Aguilera
Journal:  Clin Cancer Drugs       Date:  2015

2.  Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting BAD-Mediated caspase-3-Dependent Apoptosis.

Authors:  Hyoji Kim; Hoyun Choi; Suk Kyeong Lee
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

3.  Arsenicals, the Integrated Stress Response, and Epstein-Barr Virus Lytic Gene Expression.

Authors:  Jaeyeun Lee; Jennifer Stone; Prashant Desai; John G Kosowicz; Jun O Liu; Richard F Ambinder
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

Review 4.  Epstein-Barr Virus: Diseases Linked to Infection and Transformation.

Authors:  Hem C Jha; Yonggang Pei; Erle S Robertson
Journal:  Front Microbiol       Date:  2016-10-25       Impact factor: 5.640

Review 5.  Arsenic in medicine: past, present and future.

Authors:  Ngozi P Paul; Adriana E Galván; Kunie Yoshinaga-Sakurai; Barry P Rosen; Masafumi Yoshinaga
Journal:  Biometals       Date:  2022-02-21       Impact factor: 3.378

6.  TRIM19/PML Restricts HIV Infection in a Cell Type-Dependent Manner.

Authors:  Tanja Kahle; Bianca Volkmann; Kristin Eissmann; Alexandra Herrmann; Sven Schmitt; Sabine Wittmann; Laura Merkel; Nina Reuter; Thomas Stamminger; Thomas Gramberg
Journal:  Viruses       Date:  2015-12-23       Impact factor: 5.048

7.  Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.

Authors:  Wan-Ru Zhang; Yu-Yun Du; Chun-Yan Guo; Han-Xing Zhou; Jie-Yi Lin; Xiao-Han Meng; Hao-Yuan Mo; Dong-Hua Luo
Journal:  Cancer Res Treat       Date:  2021-01-13       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.